期刊
EXPERT OPINION ON THERAPEUTIC PATENTS
卷 33, 期 4, 页码 323-337出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/13543776.2023.2216381
关键词
ALK inhibitors; anaplastic lymphoma kinase; cancer therapy; drug resistance; patent review
This paper provides a comprehensive review of the patent literature from 2018 to 2022 regarding small molecular ALK inhibitors, including their structures, pharmacological data, and utilization as anticancer agents. It also describes several potential ALK inhibitors on the market or under clinical investigations in detail.
IntroductionAnaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor superfamily, has emerged as a promising drug target for multiple cancers. Up to now, a total of seven ALK inhibitors have been approved for clinical cancer treatment. However, the issue of resistance to ALK inhibitors was subsequently reported, which led to the exploration of novel generations of ALK inhibitors recently.Areas coveredThis paper provides a comprehensive review of the patent literature from 2018 to 2022 about structures, pharmacological data of small molecular ALK inhibitors, and their utilization as anticancer agents. In addition, several potential ALK inhibitors on the market or under clinical investigations are described in detail.Expert opinionTo date, there are no ALK inhibitors that have been approved are completely free of resistance issues, which is a plight needing urgent solution. Development of new ALK inhibitors through structure modification, multi-targeted inhibitors, type-I1/2 and type-II binding modes, as well as PROTAC and drug conjugates are proceeding. Over the last 5 years, lorlatinib, entrectinib, and ensartinib have been approved, and an increasing number of studies on ALK inhibitors, especially on macrocyclic compounds, have demonstrated their promising therapeutic potency.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据